Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Esophageal Neoplasms × nimotuzumab × Clear all

Phase

Phase 2 8 Phase 3 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Neoplasm Metastasis 1 Esophageal Neoplasms 1 Adenocarcinoma 1

Interventions

Cisplatin 7 Radiotherapy 5 Paclitaxel 3 Fluorouracil 3 Capecitabine 3 S 1 (combination) 2 tegafur-gimeracil-oteracil 1 nimotuzumab 1 nedaplatin 1 apatinib 1 TP protocol 1 Surgical Procedures, Operative 1 Oxaliplatin 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Immunotherapy 1 Fluorodeoxyglucose F18 1 Drug Therapy 1 Cetuximab 1 Carboplatin 1 CP protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡